ClinicalTrials.gg
CompletedNCT01603082Updated Dec 11, 2015Results posted

Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients

A Phase 4 interventional study of Ticagrelor and Clopidogrel in Acute Coronary Syndrome, sponsored by AstraZeneca. Completed at 16 sites in United States. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2015-12-11.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
343
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 67 studies testing ticagrelor in Acute Coronary Syndrome — 6 open to participants now, 8 under way, 1 of them phase 3. Ticagrelor · Acute Coronary Syndrome.

Enrollment
24th of 67
343 · median 120
Started
2012
with 6 others
Phase 4
38 of 67
5 open now
Registered
5th of 67
by date
Lead sponsor
8 of 67
AstraZeneca

Among the 67 studies testing ticagrelor in Acute Coronary Syndrome, this one is the 24th largest by enrollment, is one of 7 that started in 2012, is one of 38 in phase 4, and was the 5th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 273 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

6 of the 67 studies testing ticagrelor in Acute Coronary Syndrome are open now, in 7 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About ticagrelor

Ticagrelor: first FDA approval 2011 (BRILINTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 196 Acute Coronary Syndrome studies recruiting now, 145 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies testing ticagrelor in Acute Coronary Syndrome, or all of them as a file.
02

Study summary

The purpose of this study is to assess the pharmacodynamic effect of ticagrelor in ACS patients undergoing an Ad Hoc PCI

Read the detailed description

A randomized, open-label, multiple-center, parallel group study to compare the platelet inhibition with VerifyNow assay of ticagrelor versus clopidogrel in troponin negative Acute Coronary Syndrome (ACS) subjects undergoing Ad Hoc percutaneous coronary intervention (PCI)

03

Conditions studied

  • Acute Coronary Syndrome
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated before initiation of any study-related procedures
  • Male or female patients aged 18 years or older
  • Documented acute coronary syndrome and troponin negative and undergoing Ad Hoc percutaneous coronary intervention (PCI)
  • Females must be post menopausal or surgically sterile
  • Taking aspirin as an anti- medication

Exclusion criteria

Exclusion Criteria:

  • Use of any thienopyridine or ticagrelor within 7 days prior to randomization
  • Any indication for oral anticoagulant (e.g., atrial fibrillation, mitral stenosis or prosthetic heart valve)
  • that ticagrelor or clopidogrel should not be administered Patient requires dialysis
  • History of intolerance or allergy to aspirin
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
343 participants (actual)

Study arms

  • Experimental
    Ticagrelor

    Ticagrelor - 180 mg loading dose

    Drug: Ticagrelor

  • Active comparator
    Clopidogrel

    Clopidogrel - 600 mg loading dose

    Drug: Clopidogrel

Interventions

06

What researchers measure

Primary outcomes

  1. Inhibition of the P2Y12 Receptor at 2 Hours After Loading Doses of Ticagrelor and Clopidogrel as Measured by P2Y12 Reaction Units (PRU) From VerifyNow™

    Participants with low (\<150) baseline PRU values were excluded.

    Time frame: 2 hours after the loading dose

Secondary outcomes

  1. Inhibition of the P2Y12 Receptor at 0.5 Hours, End of PCI, and 8 Hours After Loading Doses of Ticagrelor and Clopidogrel as Measured by PRU From VerifyNow™

    Participants with low (\<150) baseline PRU values were excluded.

    Time frame: 0.5 hours, end of PCI, and 8 hours after the loading dose

07

Results

Posted Dec 11, 2015

Participant flow

Participants recruited from 15 actively participating sites in the United States of America, from July 2012 until June 2014.

Participant flow — Overall Study
MilestoneTicagrelorClopidogrel
Started5149
Completed4948
Not completed21
Withdrew: Adverse event01
Withdrew: Withdrawal by subject10
Withdrew: Failed inclusion criterion after dosed10

Outcome measures

PrimaryInhibition of the P2Y12 Receptor at 2 Hours After Loading Doses of Ticagrelor and Clopidogrel as Measured by P2Y12 Reaction Units (PRU) From VerifyNow™

Participants with low (\<150) baseline PRU values were excluded.

Time frame:
2 hours after the loading dose
Reported as:
Mean · PRU
Inhibition of the P2Y12 Receptor at 2 Hours After Loading Doses of Ticagrelor and Clopidogrel as Measured by P2Y12 Reaction Units (PRU) From VerifyNow™
PRUTicagrelorClopidogrel
Inhibition of the P2Y12 Receptor at 2 Hours After Loading Doses of Ticagrelor and Clopidogrel as Measured by P2Y12 Reaction Units (PRU) From VerifyNow™98.4 ± 95.4257.5 ± 74.5
Statistical analysis
  • Ticagrelor vs Clopidogrel · t-test, 2 sided · p = <0.001 · Mean difference (final values): -159.1 · 95% CI -194.7 to -123.5Ticagrelor minus clopidogrel.
SecondaryInhibition of the P2Y12 Receptor at 0.5 Hours, End of PCI, and 8 Hours After Loading Doses of Ticagrelor and Clopidogrel as Measured by PRU From VerifyNow™

Participants with low (\<150) baseline PRU values were excluded.

Time frame:
0.5 hours, end of PCI, and 8 hours after the loading dose
Reported as:
Mean · PRU
Inhibition of the P2Y12 Receptor at 0.5 Hours, End of PCI, and 8 Hours After Loading Doses of Ticagrelor and Clopidogrel as Measured by PRU From VerifyNow™
PRUTicagrelorClopidogrel
0.5 hours277.3 ± 73.8297.7 ± 69.2
8 hours43.8 ± 45.7202.3 ± 89.1
End of PCI (n=41 for ticagrelor)264.2 ± 92.2307.8 ± 59.5
Statistical analysis
  • Ticagrelor vs Clopidogrel · t-test, 2 sided · p = 0.182 · Mean difference (final values): -20.4 · 95% CI -50.5 to 9.7Ticagrelor minus clopidogrel.
  • Ticagrelor vs Clopidogrel · t-test, 2 sided · p = <0.001 · Mean difference (final values): -158.5 · 95% CI -189.4 to -127.7Ticagrelor minus clopidogrel.
  • Ticagrelor vs Clopidogrel · t-test, 2 sided · p = 0.010 · Mean difference (final values): -43.6 · 95% CI -76.5 to -10.7Ticagrelor minus clopidogrel.

Adverse events

Collected over All adverse events (AEs), including serious AEs were monitored from the point of informed consent through the 14 day follow up period. All vascular events were assessed at each visit and could be reported by participants at any time during the study.. Non-serious events are listed at a 2.5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ticagrelor—9/51 (17.6%)5/51 (9.8%)
Clopidogrel—5/49 (10.2%)1/49 (2%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventTicagrelorClopidogrel
Angina unstableCardiac disorders0/513/49
Chest painGeneral disorders2/511/49
HypotensionVascular disorders2/510/49
PneumoniaInfections and infestations0/511/49
Coronary artery diseaseCardiac disorders0/511/49
FallInjury, poisoning and procedural complications0/511/49
DuodenitisGastrointestinal disorders1/510/49
Lactic acidosisMetabolism and nutrition disorders1/510/49
Grand mal convulsionNervous system disorders1/510/49
Partial seizuresNervous system disorders1/510/49
Most frequent other events
Most frequent other events
EventTicagrelorClopidogrel
Chest painGeneral disorders2/510/49
DyspnoeaRespiratory, thoracic and mediastinal disorders2/511/49
HaematomaVascular disorders2/510/49

Baseline characteristics

Randomized Analysis Set, defined as all participants who signed informed consent, who provided demographic and/or baseline screening assessments, and who were randomized into the study regardless of the participant's randomization and treatment status in the study.

Age, Categorical
Age, Categorical(Participants)TicagrelorClopidogrelTotal
<=18 years000
Between 18 and 65 years363066
>=65 years151934
Sex: Female, Male
Sex: Female, Male(Participants)TicagrelorClopidogrelTotal
Female171330
Male343670
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)TicagrelorClopidogrelTotal
American Indian or Alaska Native101
Asian123
Black or African American111122
White333366
Missing values538
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)TicagrelorClopidogrelTotal
Hispanic or Latino516
Not Hispanic or Latino111425
Not Reported282755
Missing values7714
Region of Enrollment
Region of Enrollment(Participants)TicagrelorClopidogrelTotal
United States5149100
08

Study locations

16 sites
  • Research Site
    Birmingham, Alabama, United States
  • Research Site
    San Francisco, California, United States
  • Research Site
    Washington, District of Columbia, United States
  • Research Site
    Jacksonville, Florida, United States
  • Research Site
    Ypsilanti, Michigan, United States
  • Research Site
    Minneapolis, Minnesota, United States
  • Research Site
    Tupelo, Mississippi, United States
  • Research Site
    North Kansas, Missouri, United States
  • Research Site
    Belleville, New Jersey, United States
  • Research Site
    Bronx, New York, United States
  • Research Site
    New York, New York, United States
  • Research Site
    Greensboro, North Carolina, United States
  • Research Site
    Cincinnati, Ohio, United States
  • Research Site
    Oklahoma City, Oklahoma, United States
  • Research Site
    Tyler, Texas, United States
  • Research Site
    Richmond, Virginia, United States
09

References and documents

Publications

  • Sweeny JM, Angiolillo DJ, Franchi F, Rollini F, Waksman R, Raveendran G, Dangas G, Khan ND, Carlson GF, Zhao Y, Teng R, Mehran R. Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention. J Am Heart Assoc. 2017 Mar 29;6(4):e005650. doi: 10.1161/JAHA.117.005650. PubMed 28356282 ↗
  • Angiolillo DJ, Franchi F, Waksman R, Sweeny JM, Raveendran G, Teng R, Zhao Y, Carlson G, Khan N, Mehran R. Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI. J Am Coll Cardiol. 2016 Feb 16;67(6):603-613. doi: 10.1016/j.jacc.2015.11.044. PubMed 26868683 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of Jun 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2015, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2012
First posted
May 22, 2012
Start
Jul 2012
Primary completionActual
Jun 2014
CompletionActual
Jun 2014
Results first posted
Dec 11, 2015
Last update
Dec 11, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01603082
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
May 22, 2012
Start date
Jul 2012
Primary completion
Jun 2014
Completion
Jun 2014
Results posted
Dec 11, 2015
Last update
Dec 11, 2015

Study contacts

Glenn F. Carlson, MD
study director · AstraZeneca Pharmaceuticals, Wilmington, DE 19850-5437 USA

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ticagrelor

Start the discussion